Medicare makes changes to coverage of controversial Alzheimer’s drug Aduhelm

According to CNN article published April 7th, 2022 “Medicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services.”

To read the full article click here.

Related Articles